The value of pre-operative magnetic resonance spectroscopy in the assessment of steatohepatitis in patients with colorectal liver metastasis
2012 (English)In: J Hepatol, Vol. 56, no 3, 640-6 p.Article in journal (Refereed) Published
BACKGROUND & AIMS: Neoadjuvant chemotherapy prior to liver surgery for colorectal metastases can cause marked steatosis (>/= 33%) and steatohepatitis defined by non-alcoholic fatty liver disease activity score (NAS) as adverse effects on liver parenchyma. The aim of this study was to evaluate the steatosis level prior to liver resection using proton magnetic resonance spectroscopy ((1)H MRS) and to compare it with digital quantification of steatosis (DQS) and "classical" histopathology. METHODS: (1)H MRS at 3T evaluated steatosis in 35 patients with colorectal liver metastasis, planned for liver resection. Non-tumorous liver parenchyma samples were obtained after surgery for classical histopathology and DQS utilising automated software for quantification of histopathological slides using image processing. RESULTS: Classical histopathology defined marked steatosis in nine patients. Histopathology was less reliable than DQS (interclass correlation coefficient - ICC 0.771) or (1)H MRS (ICC 0.722) in steatosis estimation. (1)H MRS showed very similar steatosis levels and high reliability compared to DQS (ICC 0.955). Steatohepatitis was observed in seven patients (NAS >/= 4) and (1)H MRS was able to predict it with 100% sensitivity and 89% specificity at threshold 10.9%, without knowing lobular inflammation or hepatocyte ballooning. BMI was significantly higher in the groups with marked steatosis and steatohepatitis. Standard blood tests or chemotherapy had no predictive value. CONCLUSIONS: (1)H MRS is a reliable non-invasive tool for steatosis assessment, and interestingly, it was able to predict steatohepatitis defined by NAS >/= 4 in patients planned for liver resection of colorectal metastases after neoadjuvant chemotherapy.
Place, publisher, year, edition, pages
2012. Vol. 56, no 3, 640-6 p.
Aged, Colorectal Neoplasms/*pathology, Fatty Liver/*pathology, Female, Humans, Liver/*pathology, Liver Cirrhosis/pathology, Liver Neoplasms/*secondary, Magnetic Resonance Imaging/*methods/*standards, Male, Middle Aged, Predictive Value of Tests, Preoperative Care/methods/standards, Prospective Studies, Protons/diagnostic use, Reproducibility of Results, Severity of Illness Index
IdentifiersURN: urn:nbn:se:umu:diva-110934ISBN: 1600-0641 (Electronic) 0168-8278 (Linking)OAI: oai:DiVA.org:umu-110934DiVA: diva2:865841
Urdzik, Jozef Bjerner, Tomas Wanders, Alkwin Weis, Jan Duraj, Frans Haglund, Ulf Noren, Agneta eng Clinical Trial Research Support, Non-U.S. Gov't Validation Studies England 2011/10/27 06:00 J Hepatol. 2012 Mar;56(3):640-6. doi: 10.1016/j.jhep.2011.10.006. Epub 2011 Oct 23.2015-10-292015-10-292015-10-29